1. Pink Sheet
  2. >>Geography
  3. >>Europe

Pharmalink’s $15M Series C Financing To Progress Assets And Strategy

 
• By Sten Stovall

Privately held Pharmalink of Sweden will use a $15 million Series C funding for pivotal studies in its lead cancer and renal disease drugs, and to shop for new in-licensing or M&A opportunities in the Nordic region.

Pharmalink AB, a specialty Scandinavian biotech focused on orphan and niche products, has raised SEK96 million ($15 million) in a Series C financing round for use in pivotal trials for its Nefecon (budesonide) kidney drug and the oncology asset Busulipo (MZH-2). It also will use the money to explore fresh in-licensing and acquisition prospects in the region.

Cancer treatment Busulipo, a conditioning agent for use before hematopoietic stem cell transplants, was discovered by two professors at Sweden’s Karolinska Institute for use in children with malignancies or metabolic disorders who needed bone-marrow transplantation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

More from Geography